(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 September 2024 (26.09.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/197119 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/00* (2006.01)
A61P 11/00 (2006.01)

(21) International Application Number:
PCT/US2024/020860

(22) International Filing Date:
21 March 2024 (21.03.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/453,786	22 March 2023 (22.03.2023)	US
63/457,188	05 April 2023 (05.04.2023)	US
63/460,981	21 April 2023 (21.04.2023)	US
63/525,197	06 July 2023 (06.07.2023)	US
63/602,616	26 November 2023 (26.11.2023)	US
24315012.5	12 January 2024 (12.01.2024)	EP
63/551,557	09 February 2024 (09.02.2024)	US
24315047.1	14 February 2024 (14.02.2024)	EP

(71) Applicants: **SANOFI BIOTECHNOLOGY** [FR/FR]; 82 avenue Raspail, 94250 Gentilly (FR). **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **ABDULAI, Raolat**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **LAWS, Elizabeth**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **MANNENT, Leda**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **ROBINSON, Lacey**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **RUDDY, Marcella**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (US).

(74) Agent: **STONE-HULSLANDER, Judith** et al.; LATHROP GPM LLP, 28 STATE STREET, Boston, Massachusetts 02109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2024/197119 A1

(54) Title: METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BY ADMINISTERING AN IL-4R ANTAGONIST

(57) Abstract: Methods for treating or preventing chronic obstructive pulmonary disease (COPD) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.